chlorthalidone has been researched along with Hypertrophy, Left Ventricular in 21 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment." | 9.22 | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial. ( Alves, JG; Berwanger, O; Bordignon, A; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Consolim-Colombo, FM; de Alencastro, PR; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Mota Gomes, M; Neto, AA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Silva, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 9.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 8.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| "To evaluate the effects of the use of chlorthalidone on left ventricular mass of patients with mild and moderate systemic arterial hypertension (SAH)." | 7.68 | [Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension]. ( César, LA; da Luz, PL; Francischetti, E; Mansur, Ade P; Marcondes, M; Oigman, W; Pileggi, F; Ramires, JA, 1993) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 6.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| " Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment." | 5.22 | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial. ( Alves, JG; Berwanger, O; Bordignon, A; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Consolim-Colombo, FM; de Alencastro, PR; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Mota Gomes, M; Neto, AA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Silva, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 5.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 4.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| "To evaluate the effects of the use of chlorthalidone on left ventricular mass of patients with mild and moderate systemic arterial hypertension (SAH)." | 3.68 | [Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension]. ( César, LA; da Luz, PL; Francischetti, E; Mansur, Ade P; Marcondes, M; Oigman, W; Pileggi, F; Ramires, JA, 1993) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 2.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, CN | 1 |
| Soliman, EZ | 3 |
| Simpson, LM | 1 |
| Davis, BR | 3 |
| Devereux, RB | 1 |
| Okin, PM | 2 |
| Hayer, MK | 1 |
| Edwards, NC | 1 |
| Slinn, G | 1 |
| Moody, WE | 1 |
| Steeds, RP | 1 |
| Ferro, CJ | 1 |
| Price, AM | 1 |
| Andujar, C | 1 |
| Dutton, M | 1 |
| Webster, R | 1 |
| Webb, DJ | 1 |
| Semple, S | 1 |
| MacIntyre, I | 1 |
| Melville, V | 1 |
| Wilkinson, IB | 1 |
| Hiemstra, TF | 1 |
| Wheeler, DC | 1 |
| Herrey, A | 1 |
| Grant, M | 1 |
| Mehta, S | 1 |
| Ives, N | 1 |
| Townend, JN | 1 |
| Roush, GC | 4 |
| Abdelfattah, R | 2 |
| Song, S | 2 |
| Kostis, JB | 3 |
| Ernst, ME | 6 |
| Sica, DA | 3 |
| Tadic, M | 1 |
| Cuspidi, C | 1 |
| Kuusela, PJ | 1 |
| Johnson, K | 1 |
| Oparil, S | 2 |
| Tereshchenko, LG | 1 |
| Buddharaju, V | 1 |
| Kaur, R | 1 |
| Prineas, RJ | 2 |
| Ghosh, A | 1 |
| Cushman, WC | 1 |
| Einhorn, PT | 1 |
| Grimm, RH | 2 |
| Fuchs, SC | 1 |
| Poli-de-Figueiredo, CE | 1 |
| Figueiredo Neto, JA | 1 |
| Scala, LC | 1 |
| Whelton, PK | 1 |
| Mosele, F | 1 |
| de Mello, RB | 1 |
| Vilela-Martin, JF | 1 |
| Moreira, LB | 1 |
| Chaves, H | 1 |
| Mota Gomes, M | 1 |
| de Sousa, MR | 1 |
| Silva, RP | 1 |
| Castro, I | 1 |
| Cesarino, EJ | 1 |
| Jardim, PC | 1 |
| Alves, JG | 1 |
| Steffens, AA | 1 |
| Brandão, AA | 1 |
| Consolim-Colombo, FM | 1 |
| de Alencastro, PR | 1 |
| Neto, AA | 1 |
| Nóbrega, AC | 1 |
| Franco, RS | 1 |
| Sobral Filho, DC | 1 |
| Bordignon, A | 1 |
| Nobre, F | 1 |
| Schlatter, R | 1 |
| Gus, M | 1 |
| Fuchs, FC | 1 |
| Berwanger, O | 1 |
| Fuchs, FD | 1 |
| Kaplan, NM | 1 |
| Neaton, JD | 1 |
| Collins, G | 1 |
| Thomas, W | 1 |
| Rakić, D | 1 |
| Rumboldt, Z | 1 |
| Bagatin, J | 1 |
| Polić, S | 1 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Witham, MD | 1 |
| Davies, JI | 1 |
| Dawson, A | 1 |
| Davey, PG | 1 |
| Struthers, AD | 1 |
| González-Juanatey, JR | 1 |
| Pose Reino, A | 1 |
| Amaro Cendón, A | 1 |
| García Acuña, JM | 1 |
| Castelo Fuentes, V | 1 |
| Calvo Gómez, C | 1 |
| de la Peña, MG | 1 |
| Ranieri, G | 1 |
| Taddei, S | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 1 |
| Salvetti, A | 1 |
| Ramires, JA | 1 |
| Mansur, Ade P | 1 |
| Oigman, W | 1 |
| Francischetti, E | 1 |
| César, LA | 1 |
| Marcondes, M | 1 |
| da Luz, PL | 1 |
| Pileggi, F | 1 |
| Ofili, EO | 1 |
| Cohen, JD | 1 |
| St Vrain, JA | 1 |
| Pearson, A | 1 |
| Martin, TJ | 1 |
| Uy, ND | 1 |
| Castello, R | 1 |
| Labovitz, AJ | 1 |
| De Rosa, ML | 1 |
| Giordano, A | 1 |
| Della Guardia, D | 1 |
| Maddaluno, G | 1 |
| Lionetti, F | 1 |
| Marsicani, N | 1 |
| Vigorito, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study[NCT00970931] | Phase 3 | 730 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for chlorthalidone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Diuretics, Potassium Spari | 2018 |
Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics, Potassium Sparing; Drug Therapy, | 2018 |
Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2013 |
12 trials available for chlorthalidone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
Topics: Adult; Aged; Chlorthalidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fo | 2017 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Electrocardiography; Female; Humans; Hype | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Combined Modality Therapy; Diuretics | 2011 |
Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Croatia; Echocardiography; Female; Heart Ventr | 2002 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
[The midterm inefficacy of 2 different dosages of chlorthalidone (50 and 25 mg/day) in the regression of left ventricular mass in arterial hypertension].
Topics: Aged; Atenolol; Blood Pressure; Chi-Square Distribution; Chlorthalidone; Enalapril; Follow-Up Studie | 1995 |
The effects of diuretic and beta-blocker treatment on cardiac and vascular structural changes in untreated essential hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Hypertrophy, Left Ven | 1993 |
Effect of treatment of isolated systolic hypertension on left ventricular mass.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Female; Follow-Up Studies; Heart | 1998 |
Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Chi-Square Distribution; Chlorthalidone; Drug Therapy, Combination; E | 1999 |
6 other studies available for chlorthalidone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Diuretics and left ventricular hypertrophy regression: The relationship that we commonly forget.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hyper | 2018 |
Interventricular vessel of the heart and diuretics.
Topics: Chlorthalidone; Diuretics; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, | 2019 |
Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension.
Topics: Animals; Blood Pressure; Chlorthalidone; Evidence-Based Practice; Heart Failure; Humans; Hypertensio | 2015 |
Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Electrocardiography; Humans; Hydrochlorothiazide | 2011 |
Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cost-Benefit Analysis; Echocardiog | 2004 |
[Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension].
Topics: Adult; Blood Pressure; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left V | 1993 |